Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131.

Philip Young, CEO of Lobe Sciences stated, “We have made significant progress toward initiating our first human trials with our proprietary psilocin analog L-130 and pre clinical plans for L-131. These updates can be found at our Company website https://www.lobesciences.com/corporate-profile/company-presentation/. We believe that Lobe is beginning to be recognized as one of the leading companies developing stable psilocin compounds as noted in leading Biotech publications such as Fierce Biotech, https://www.fiercebiotech.com/biotech/canadian-biotech-lobe-sciences-taps-australian-cro-ingenu-psychedelic-drug-trial. This is an exciting time for all stakeholders and I look forward to continuing to update the investment community as we advance our plans for developing novel drugs for patients around the globe.”

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.